» Articles » PMID: 16873726

Close Approximation of Two Platelet Factor 4 Tetramers by Charge Neutralization Forms the Antigens Recognized by HIT Antibodies

Overview
Date 2006 Jul 29
PMID 16873726
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Heparin-induced thrombocytopenia (HIT) is a prothrombotic drug reaction caused by antibodies that recognize positively charged platelet factor 4 (PF4), bound to the polyanion, heparin. The resulting immune complexes activate platelets. Unfractionated heparin (UFH) causes HIT more frequently than low-molecular-weight heparin (LMWH), whereas the smallest heparin-like molecule (the pentasaccharide, fondaparinux), induces anti-PF4/heparin antibodies as frequently as LMWH, but without exhibiting cross-reactivity with these antibodies. To better understand these findings, we analyzed the molecular structure of the complexes formed between PF4 and UFH, LMWH, or fondaparinux.

Methods And Results: By atomic force microscopy and photon correlation spectroscopy, we show that with any of the 3 polyanions, but in the order, UFH>LMWH>>fondaparinux--PF4 forms clusters in which PF4 tetramers become closely apposed, and to which anti-PF4/heparin antibodies bind. By immunoassay, HIT antibodies bind strongly to PF4/H/PF4 complexes, but only weakly to single PF4/heparin molecules.

Conclusions: HIT antigens are formed when charge neutralization by polyanion allows positively charged PF4 tetramers to undergo close approximation. Whereas such a model could explain why all 3 polyanions form antibodies with similar specificities, the striking differences in the relative size and amount of complexes formed likely correspond to the observed differences in immunogenicity (UFH>LMWH approximately fondaparinux) and clinically relevant cross-reactivity (UFH>LMWH>>fondaparinux).

Citing Articles

Unraveling Cardiovascular Risks and Benefits of COVID-19 Vaccines: A Systematic Review.

Satyam S, El-Tanani M, Bairy L, Rehman A, Srivastava A, Kenneth J Cardiovasc Toxicol. 2025; 25(2):306-323.

PMID: 39826014 DOI: 10.1007/s12012-024-09954-2.


Complement activation as a biomarker for platelet-activating antibodies in heparin-induced thrombocytopenia.

Myoung S, Francis S, Chen J, Lee G, Rauova L, Poncz M J Thromb Haemost. 2024; 23(3):1066-1076.

PMID: 39725085 PMC: 11890944. DOI: 10.1016/j.jtha.2024.12.015.


Molecular architecture and platelet-activating properties of small immune complexes assembled on heparin and platelet factor 4.

Yang Y, Du Y, Ivanov D, Niu C, Clare R, Smith J Commun Biol. 2024; 7(1):308.

PMID: 38467823 PMC: 10928113. DOI: 10.1038/s42003-024-05982-4.


Autoimmune Heparin-Induced Thrombocytopenia.

Warkentin T J Clin Med. 2023; 12(21).

PMID: 37959386 PMC: 10649402. DOI: 10.3390/jcm12216921.


Laboratory Testing for Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia Antibodies: A Narrative Review.

Warkentin T, Greinacher A Semin Thromb Hemost. 2022; 49(6):621-633.

PMID: 36455619 PMC: 10421650. DOI: 10.1055/s-0042-1758818.